Delayed Adjuvant Chemotherapy Linked to Poorer Colorectal Cancer Survival
Delaying adjuvant chemotherapy for more than 6 weeks post colorectal cancer surgery is associated with worse disease-free survival in high-risk stage II and III patients. A study of 5719 individuals revealed a 5-year disease-free survival of 78.0% vs. 73.2% in early vs. late-start groups, respectively. Those initiating chemotherapy later had a hazard ratio of 1.24 for worse outcomes. No significant difference in adverse events was observed between the groups.
Removing the rectal tumor and liver spread in one operation did not clearly raise complications or hurt survival compared with two separate operations, a French national study found.
A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.
